- First Online:
- 109 Downloads
Perindopril (Coversyl®) is a prodrug ester of perindoprilat, an ACE inhibitor. This agent has shown pharmacodynamic effects beyond those responsible for lowering blood pressure (BP), including the improvement of endothelial function and the normalisation of vascular and cardiac structure and function.
Perindopril has a well established role in the treatment of patients with hypertension or heart failure. In the EUROPA trial, once-daily perindopril 8mg prevented cardiovascular events in patients with stable coronary artery disease (CAD) without any apparent heart failure receiving standard recommended therapy. In the ASCOT-BPLA trial, a calcium channel antagonist ± perindopril regimen demonstrated significant cardiovascular benefits compared with a conventional β-blocker ± diuretic regimen in patients with hypertension who were at risk of developing cardiovascular events. These trials demonstrate that while perindopril, in addition to standard recommended therapy, has a potential role in preventing cardiovascular events in hypertensive patients, its role in the management of patients with stable CAD is clearly established.
Perindopril is a prodrug ester of perindoprilat, an ACE inhibitor. This agent demonstrates pharmacodynamic effects beyond those responsible for lowering BP involving the improvement of endothelial dysfunction and reduction in markers of inflammation and thrombosis. In the PERTINENT trial, perindopril significantly increased plasma levels of bradykinin, and improved endothelial cell nitric oxide synthetase activity. Perindopril reduced levels of angiotensin II, D-dimer and von Willebrand factor and reduced the rate of endothelial apoptosis.
Perindopril demonstrated anti-remodelling effects in small resistance arteries, large arteries and in the heart. Perindopril reduced the media thickness-to-lumen diameter ratio of small arteries and reduced peripheral vascular resistance in patients with hypertension. In small coronary arterioles, the reduction in periarteriolar collagen area and total interstitial collagen volume density in perindopril recipients was associated with a significant increase in coronary blood flow and in coronary reserve. Long-term treatment with perindopril reduced carotid and radial artery wall hypertrophy. In patients with end-stage renal disease, perindopril, independent of BP changes, reduced aortic pulse wave velocity. In the heart, perindopril significantly reduced left ventricular mass in patients with hypertension.
Following oral administration, perindopril is rapidly absorbed, with peak plasma concentrations being reached within 1 hour. Approximately 20–50% of the perindopril absorbed is converted to the active metabolite perindoprilat. Peak plasma concentrations of perindoprilat occur after 3–7 hours; protein binding of perindoprilat is 10–20%. The apparent mean half-life for the majority of perindoprilat elimination is about 3–10 hours, but perindoprilat has a prolonged terminal elimination half-life of 30–120 hours, reflecting slow dissociation from ACE binding sites. Perindoprilat is eliminated in the urine. Food intake may reduce biotransformation of perindopril to perindoprilat.
In the randomised, double-blind EUROPA trial, 12 218 patients with stable CAD and without heart failure were randomised to once-daily perindopril 8mg or placebo. After a mean follow-up of 4.2 years, a significant (p = 0.0003) relative risk reduction (RRR) of 20% for the primary endpoint (cardiovascular death, nonfatal myocardial infarction [MI] and resuscitated cardiac arrest) occurred with perindopril versus placebo. This benefit was consistent in predefined subgroups and was irrespective of treatment with other standard recommended therapy, including platelet inhibitors, lipid-lowering agents and β-blockers.
In the 12-month, randomised, double-blind PREAMI trial in 1252 elderly patients with recent MI and preserved left ventricular ejection fraction, once-daily perindopril 8mg, compared with placebo, was associated with a significant RRR of 38% (p < 0.001) for the primary endpoint (death, hospitalisation for heart failure and cardiac remodelling). Significantly less left ventricular remodelling occurred in perindopril recipients than in placebo recipients (27.7% vs 51.2%, RRR 46%; p < 0.001).
In the randomised, double-blind PROGRESS study in 6105 patients with a previous history of stroke or transient ischaemic attack, the risk of stroke was 10% in recipients of perindopril ± indapamide and 14% in placebo recipients (RRR 28%; p < 0.0001) over a mean follow-up of 3.9 years. BP was reduced by 9/ 4mm Hg in recipients of perindopril ± indapamide compared with placebo. Perindopril ± indapamide reduced the risk of nonfatal myocardial infarction by 38% (95% CI 14, 55) and congestive heart failure by 26% (p = 0.02).
The randomised, open-label ASCOT-BPLA trial in 19 257 hypertensive patients at moderate risk of developing cardiovascular events was terminated prematurely (median follow-up of 5.5 years) because the risk reduction of all-cause mortality was 11 % lower in those treated with amlodipine ± perindopril than in those treated with atenolol ± thiazide. The RRR of 10% for the primary endpoint (nonfatal MI and fatal CHD) in recipients of amlodipine ± perindopril was not significant; however, because of the early termination of the trial, the study was not sufficiently powered for this endpoint.
Perindopril is generally well tolerated in patients with hypertension, heart failure or CAD. Generally, adverse events were mild and transient, with cough, gastrointestinal disturbances and asthenia/fatigue (all <10%) being most commonly reported in a large (n = 47 351) postmarketing surveillance study in patients with hypertension. In the EUROPA trial in patients with CAD, withdrawals in perindopril and placebo recipients were for cough (2.7% vs 0.5%), hypotension (1.0% vs 0.3%) or drug intolerance (2.4% vs 1.3%).
- 13.Ceconi C, Fox KM, Remme WJ, et al. Effect of perindopril in patients with stable coronary artery disease: results of the PERTINENT Sub-Study [abstract no.3665]. J Hypertens 2005 Jun; 23 Suppl. 2: 274Google Scholar
- 18.Bots ML, Remme WJ, Grobbee DE, et al. ACE inhibition and endothelial function in the EUROPA Trial: the main findings from the PERFECT substudy [abstract no. 825-8]. J Am Coll Cardiol 2005 Feb 1; 45 (3 Suppl. A): 409Google Scholar
- 19.Ferrari R, Remme WJ, EUROPA Investigators, et al. PERTINENT; PERindopril — Thrombosis, InflammatioN, Endothelial dysfunction and Neurohormonal activation Trial [online]. Available from URL: http://www.europa-trial.org/pro/pertinent/pertinent_findings.asp [Accessed 2005 Oct 25]
- 20.Asmar R, Topouchian J, Pannier B, et al. Pulse wave velocity as endpoint in large-scale intervention trial: the Complior study. Scientific, Quality Control, Coordination and Investigation Committees of the Complior Study. J Hypertens 2001 Apr; 19(4): 813–8Google Scholar
- 25.Tropeano A, Boutouyrie P, Pannier B, et al. Pressure-independent and dose-dependent remodelling of the carotid artery after perindopril in diabetic hypertensive patients. J Hypertens 2005; 23 Suppl. 2: S225Google Scholar
- 30.Grandi AM, Venco A, Barzizza F, et al. Double-blind comparison of perindopril and captopril in hypertension. Effects on left ventricular morphology and function. Am J Hypertens 1991 Jun; 4(6): 516–20Google Scholar
- 34.London GM, Pannier B, Guerin AP, et al. Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade. Circulation 1994 Dec; 90(6): 2786–96Google Scholar
- 35.Overlack A, Adamczak M, Bachmann W, et al. ACE-inhibition with perindopril in essential hypertensive patients with concomitant diseases. The Perindopril Therapeutic Safety Collaborative Research Group. Am J Med 1994 Aug; 97(2): 126–34Google Scholar
- 37.Williams B. Differential impact of the blood pressure lowering drugs on central arterial pressure influences clinical outcomes — principle results of the Conduit Artery Function Evaluation [late breaker abstract no. PS.01 plus oral presentation]. 78th Scientific Sessions of the American Hypertension Association; 2005 Nov 13; Dallas (TX)Google Scholar
- 38.Servier Laboratories Ltd. Coversyl®: summary of product characteristics [online]. Available from URL: http://www.emc.medicines.org.uk [Accessed 2005 Nov 4]
- 39.Solvay Pharmaceuticals Inc. Aceon: US prescribing and safety information [online]. Available from URL: http://www.solvaypharmaceuticals-us.com [Accessed 2005 Nov 4]
- 42.Ferrari R. PREAMI: Perindopril and Remodelling in Elderly with Acute Myocardial Infarction. European Society of Cardiology Congress 2005: hotline session: (abstract plus oral presentation), 2005 4 Sep; Stockholm [online]. Available from: URL: http://cic.escardio.org [Accessed 2005 Sep 14]Google Scholar
- 43.PROGRESS Collaborative Group. Effects of a perindopril-based blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease. Eur Heart J 2003 Mar; 24(5): 475–84Google Scholar
- 44.Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOTBPLA): a multicentre randomised controlled trial. Lancet 2005 Sep 10; 366(9489): 895–906PubMedCrossRefGoogle Scholar
- 45.Fox KM. Management of coronary artery disease: implications of the EUROPA trial. Br J Cardiol 2004; 11(3): 195–204Google Scholar
- 46.EUROPA Investigators. EUROPA; European trial on Reduction Of cardiac evens with Perindopril in stable coronary Artery disease [online]. Available from URL: http://www.europa-trial.org [Accessed 2005 Nov 4]
- 48.Fox, K. Prevention of events in coronary artery disease with ACE inhibitors: new insights from EUROPA. Oral symposium presented at European Society of Cardiology Congress; 2005 Sept 5; StockholmGoogle Scholar
- 49.Bertrand ME, Remme WJ, Fox KM, et al. Effects of perindopril on long-term clinical outcome of patients with coronary artery disease and preserved left ventricular function: the EUROPA study [abstract no. P3489]. Annual Congress of the European Society of Cardiology; 2005 Sep 3–7; StockholmGoogle Scholar
- 50.Deckers JW, Goedhart DM, Bertrand ME, et al. Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk [abstract no. 3663]. Annual Congress of the European Society of Cardiology; 2005 Sep 3–7; StockholmGoogle Scholar
- 51.Cleland JG, Coletta AP, Lammiman M, et al. Clinical trials update from the European Society of Cardiology meeting 2005: CARE-HF extension study, ESSENTIAL, CIBIS-III, SICD, ISSUE-2, STRIDE-2, SOFA, IMAGINE, PREAMI, SIRIUS-II and ACTIVE. Eur J Heart Fail 2005 Oct; 7(6): 1070–5PubMedCrossRefGoogle Scholar
- 55.Haiat R, Piot O, Gallois H, et al. Blood pressure response to the first 36 hours of heart failure therapy with perindopril versus captopril. French General Hospitals National College of Cardiologists. J Cardiovasc Pharmacol 1999 Jun; 33(6): 953–9Google Scholar
- 57.Vitovec J, Spinar J. First-dose hypotension after angiotensin-converting enzyme (ACE) inhibitors in chronic heart failure: a comparison of enalapril and perindopril. Slovak Investigator Group. Eur J Heart Fail 2000 Sep; 2(3): 299–304Google Scholar
- 59.European Medicines Agency: Committee for Medicinal Products for Human Use. Doc. Ref. EMEA/246640/2005 [media release]. 2005Google Scholar
- 61.Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992 Sep 3; 327(10): 669–77CrossRefGoogle Scholar
- 62.Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995 Dec 21; 333(25): 1670–6Google Scholar
- 63.The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993 Oct 2; 342(8875): 821–8Google Scholar
- 65.Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-term Evaluation (SMILE) Study Investigators. N Engl J Med 1995 Jan 12; 332(2): 80–5Google Scholar
- 67.Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000 Jan 20; 342(3): 145–53Google Scholar
- 72.Bonarjee VV, Carstensen S, Caidahl K, et al. Attenuation of left ventricular dilatation after acute myocardial infarction by early initiation of enalapril therapy. CONSENSUS II Multi-Echo Study Group. Am J Cardiol 1993 Nov 1; 72(14): 1004–9Google Scholar
- 73.St John Sutton M, Pfeffer MA, Plappert T, et al. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. Circulation 1994 Jan; 89(1): 68–75Google Scholar
- 75.St John Sutton M, Pfeffer MA, Moye L, et al. Cardiovascular death and left ventricular remodeling two years after myocardial infarction: baseline predictors and impact of long-term use of captopril: information from the Survival and Ventricular Enlargement (SAVE) trial. Circulation 1997 Nov 18; 96(10): 3294–9CrossRefGoogle Scholar
- 76.Nicolosi GL, Latini R, Marino P, et al. The prognostic value of predischarge quantitative two-dimensional echocardiographic measurements and the effects of early lisinopril treatment on left ventricular structure and function after acute myocardial infarction in the GISSI-3 Trial. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico. Eur Heart J 1996 Nov; 17(11): 1646–56Google Scholar
- 77.Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guidelines update for the management of patients with chronic stable angina; a report of the American College of Cardiology/ American Heart Association task force on practice guidelines [online]. Available from URL: http://www.acc.org/clinical/guidelines/stable/stable_clean.pdf [Accessed 2005 Nov 14]
- 78.Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. Executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 2004 Aug 3; 110(5): 588–636PubMedGoogle Scholar
- 79.National Institutes for Clinical Excellence. Hypertension: management of hypertension in adults in primary care — clinical guideline 18 [online]. Available from URL: http://www.nice.org.uk/CGO18NICEguideline [Accessed 2005 Nov 24]
- 82.Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003 Dec 3; 290(21): 2805–16Google Scholar
- 88.Turnbull F. Blood pressure-independent effects for agents inhibiting the renin-angiotensin system. Plenary session. Fifteenth European Meeting on Hypertension; 2005 Jun 17–21; MilanGoogle Scholar
- 90.Novartis. Diovan® (valsartan tablets): US prescribing information. 2005 AugGoogle Scholar